Lung carcinoma is the leading cause of death by cancer worldwide. When possible, surgery
is the best treatment strategy for patients with non–small-cell lung cancer. However, even …

Immunotherapy has emerged in recent years as a promising therapeutic approach in lung
cancer. Two approaches are of particular interest: immune checkpoint inhibition, which aims …

Abstract Treatment of lung cancer remains a challenge, and lung cancer is still the leading
cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but …

Lung cancer is the leading cause of cancer-related death worldwide. Treatment of non-small
cell lung cancer has evolved tremendously over the past decade. Specifically, immune …

The three major conventional treatments: surgery, chemotherapy, and radiation therapy,
have been commonly performed for lung cancer. However, lung cancer is still the leading …

Over the last several years, new therapeutic targets have emerged in immunotherapy,
particularly the immune checkpoint pathways. Blocking inhibitory pathways via monoclonal …

Among several types of tumor, lung cancer is considered one of the most fatal and still the
main cause of cancer-related deaths. Although chemotherapeutic agents can improve …

Recent breakthroughs in translating the early development of immunomodulatory antibodies
into the clinic, notably with the anti–cytotoxic T-lymphocyte antigen-4 antibody, ipilimumab …

Lung cancer remains the most common cause of cancer-related deaths worldwide. Although
there are many possible treatments, including targeted therapies such as epidermal growth …

Emerging evidence on the role of the antitumor activity of the immune system has generated
great interest in immunotherapy even for tumors that were historically considered as …